Lab Notes: Context identifies lead cancer drug candidate; Aclaris inks licensing deal worth up to $96M

This week's Philadelphia-area life sciences industry update includes a women's oncology company identifying a lead product candidate, a biopharmaceutical company's multimillion-dollar licensing deal, a biotech firm initiating human clinical trials, and more. Here's the roundup: The Philadelphia-based women's oncology company selected CTIM-76 as its lead clinical development candidate targeting Claudin 6 (CLDN6) positive cancers. CLDN6-enriched cancers include ovarian, endometrial, testicular, …
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news